ASCO26: Atish Choudhury, MD, PhD, A-DREAM/Alliance A032101 - Quiz - MDSpire

ASCO26: Atish Choudhury, MD, PhD, A-DREAM/Alliance A032101

A-DREAM/Alliance A032101 study presented by Dana-Farber Cancer Institute's Dr. Atish Choudhury shows 41% of favorable responders to testosterone suppression plus androgen receptor pathway inhibitor remaining treatment-free with testosterone recovery at 18 months after treatment interruption.

  • July 1, 2026

Share

Original Source(s)

ASCO26: Atish Choudhury, MD, PhD, A-DREAM/Alliance A032101

  • July 1, 2026

Related Content

Development and application of a prognostic model based on radiomics and artificial intelligence for patients with lung adenocarcinoma brain metastasis

RFX5 in cancer: context-dependent molecular functions and emerging translational relevance

Correction: Olaparib-mediated enhancement of 5-fluorouracil cytotoxicity in mismatch repair deficient colorectal cancer cells